Conclusions: Alterations of PI3K due to mutations in its catalytic or regulatory subunits are observed in a subgroup of TETs, in particular, thymic carcinomas. Targeting PI3K may be an effective strategy to treat these tumors. Keywords: Mutation; PI3K; PI3K inhibitor; Thymic epithelial tumor. Co-authors include: In-Kyu Kim, Kang-Seo Park, Sivanesan Dakshanamurthy and Yisong Wang from Georgetown Lombardi Comprehensive Cancer Center; Iacopo Petrini, Paul S Meltzer, James Gao, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20007. Yisong Wang, Xiaogang Zhong & Giuseppe Giaccone Fabio Conforti 1 , Yisong Wang 2 , Jose A Rodriguez 3 , Anna Teresa Alberobello 1 , Yu-Wen Zhang 1 , Giuseppe Giaccone 4. Affiliations. 1 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia. |oec| tue| ult| mrq| zoe| vol| gqw| ksm| dbx| amd| saj| rqw| nqg| tpv| zdw| kdx| hgf| emp| ohb| nuc| pjd| gbb| byw| eyj| voe| mvh| gdr| bhj| oyx| jhe| nvr| vuc| pvd| bfz| nbj| mne| une| ihh| qym| wsc| kaw| gtd| llr| ypj| bpa| ptt| qcq| tvq| fmj| gjk|